Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Basiliximab has been a routine induction therapeutic agent even for well-matched living kidney transplantation(KT) with tacrolimus-based immunosuppression in Korea. As tacrolimus is a different drug from cyclosporine, the investigators study the usefulness of tacrolimus-based immunosuppression without basiliximab in well matched living KT.
The investigators omit basiliximab induction therapy in patients who underwent one to three-HLA mismatched living donor renal transplantation. Participants should receive ABO compatible and T-flow negative transplants. The investigators compare the results of intervention group with conventionally treated control group (age and sex matched patient who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| No basiliximab group | Experimental | The investigators omit basiliximab induction therapy in one to three-HLA mismatched living donor renal transplants. |
|
| Basilixiab group | Active Comparator | Age and sex matched patients who underwent one to three-HLA mismatched living donor renal transplants with basiliximab induction therapy (Control group) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Basiliximab | Drug | Basiliximab induction therapy |
| |
| No basiliximab |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of rejection | The investigators measures incidence of rejection by serum creatinine, urinalysis and kidney allograft biopsy. | within 3 years |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of infection | The investigators measures incidence of infection such as CMV, BKV infection, pneumonia, urinary tract infection and other infections. | postoperative 6 month, 1 year, 1.5 year, 2 years and 3 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Chung Hee Baek, M.D. | Contact | 82-2-3010-1481 | bch393@naver.com | |
| Su-Kil Park, M.D, PhD | Contact | 82-2-3010-3263 |
| Name | Affiliation | Role |
|---|---|---|
| Su-Kil Park, M.D, PhD | Asan Medical Center | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Asan Medical Center | Recruiting | Seoul | 138-736 | South Korea |
Not provided
| ID | Term |
|---|---|
| D000077552 | Basiliximab |
| D016030 | Kidney Transplantation |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
No basiliximab induction therapy |
|
| Kidney transplantation | Procedure | kidney transplantation |
|
| D007162 |
| Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D017582 | Renal Replacement Therapy |
| D013812 | Therapeutics |
| D016377 | Organ Transplantation |
| D014180 | Transplantation |
| D013514 | Surgical Procedures, Operative |
| D013520 | Urologic Surgical Procedures |
| D013519 | Urogenital Surgical Procedures |